Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Insulet Corp (NASDAQ:PODD)

During the Trading Day
35.28 +0.51 / +1.47%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
35.26 -0.0215 / -0.06%
Volume: 10.3K
Health Technology
Medical Specialties

Company Description

Insulet Corp. engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. Through its OmniPod Insulin Management System, the company seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod Insulin Management System is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. The company's current product offering consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. Insulet was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Bedford, MA.

Contact Information

Insulet Corp.
600 Technology Park Drive
Billerica Massachusetts 01730
P:(978) 600-7000
Investor Relations:
(978) 600-7717



Mutual fund holders62.69%
Other institutional45.67%
Individual stakeholders26.36%

Top Executives

Patrick J. SullivanPresident, Chief Executive Officer & Director
Mark LicariVice President-Global Manufacturing & Operations
Michael L. LevitzChief Financial Officer
Paul LucidiChief Information Officer
Howard ZisserMedical Director